CPC of America Inc. announced today the filing of its first patent of a synthetic sealant for specific application to the MedCloseTMVCS. CPC is focused on the development and testing of the MedClose VCS, which is an internal puncture-closing system for use in percutaneous intravascular diagnostic and interventional procedures. In addition, CPC is focused on the development of its own synthetic sealant product line for various clinical applications not limited to vascular closures devices.
In December 2008, CPC
announced the addition of Olex Hnojewyj, Ph D. to its team of medical and
research advisors, and in March 2009 the company announced a product
development agreement with Dr. Hnojewyj. Today, CPC announces the filing of the
first of several intellectual properties for formulations of synthetic sealant
to be used in the MedClose VCS vascular closure product line, initially with
The MedClose VCS device
consists of two parts: (1) A delivery system that delivers the sealant to the
puncture site; and (2) the synthetic sealant itself. While CPC will continue to
refine the MedClose VCS device commercially, the company is comfortable with
its effectiveness as well as its proprietary and competitive advantages.